Is metabolic dysfunction-associated fatty liver disease (MAFLD) associated with a higher prevalence of cardiovascular autonomic neuropathy in patients with type 2 diabetes?
Screening for MAFLD and high FIB-4 levels in patients with T2DM may help identify those at higher risk for cardiovascular autonomic neuropathy.
MAFLD is independently associated with a higher prevalence of DCAN in patients with T2DM. The risk was further amplified when high FIB-4 index (FIB-4 >1.3) was present among those with MAFLD. Hence, screening for MAFLD and its associated high FIB-4 levels may help identify patients with T2DM at a higher risk of DCAN.
Peng et al. (2026) studied this question.